Small interfering RNA (siRNA) therapeutics silence disease-associated genes by degrading target mRNA, offering a highly specific approach for treating a wide range of diseases. Successful development depends not only on efficient delivery technologies, such as lipid nanoparticles (LNPs) and GalNAc conjugation, but also on robust preclinical models that evaluate target engagement, pharmacological activity, and tissue-specific delivery.
Unlike conventional drugs, siRNA therapeutics exhibit unique pharmacokinetic and pharmacodynamic (PK/PD) characteristics, including rapid plasma clearance, prolonged retention in target tissues, and sustained gene-silencing effects. Because pharmacological activity is driven by intracellular siRNA-RISC complexes rather than circulating drug concentrations, preclinical studies should integrate in vitro target validation, off-target assessment, in vivo pharmacodynamic evaluation, biomarker analysis, and quantitative PK/PD modeling to support dose selection and clinical translation.
Reliable animal models, particularly non-human primates when pharmacologically relevant, play a critical role in evaluating efficacy, dose-response relationships, and translational potential. Combined with advanced PK/PD analysis and disease models, these preclinical strategies provide the scientific foundation for first-in-human studies, clinical dose optimization, and the successful development of next-generation siRNA therapeutics.
